Stay current with MiRXES
Newsroom > Media Releases
Singaporean provider of diagnostic tests and research products MiRXES launches Japan subsidiary
SINGAPORE, 1 June 2020 –
MiRXES is a Singapore-headquartered biotech company providing liquid biopsy diagnostic and precision medicine for early cancer detection, RT-PCR tests for COVID-19, as well as life science products and services.
The company offers the world’s first microRNA-based blood test for early detection of gastric cancer that is approved for commercial use. Also, MiRXES successfully mass produce the Fortitude Kit, the COVID-19 RT-PCR test kit to fight the COVID-19 outbreak in 2020. The Fortitude Kit, tested and proven in more than 80% of all hospitals in Singapore, has been deployed in more than 20 countries, including New Zealand and the United States.
MiRXES Japan K.K. was established in Chiyoda Ward, Tokyo in January 2020.
Enhancing activities in Japan not only enable the easier and more accurate diagnosis of gastric cancer which is common case in Japan, but also help to propose the best medical and precision treatment for patients in Japan through their ultra-sensitive microRNA detection.
To assist with the establishment of the company’s base in Japan, the JETRO Invest Japan Business Support Center (IBSC) provided consultation on company registration and labor matters, information on related regulations, introduction to local service providers, as well as PR related assistance.